(NP (NP (NP (NN Membrane) (NNS receptors)) (PP (IN for) (NP (NN aldosterone))) (: :)) (NP (NP (DT a) (JJ novel) (NN pathway)) (PP (IN for) (NP (NN mineralocorticoid) (NN action))) (. .)))
(S (NP-SBJ-2 (NP (JJ Rapid) (JJ nongenomic) (ADJP (FW in) (FW vitro)) (NNS effects)) (PP (IN of) (NP (NN aldosterone))) (PP (IN on) (NP-COOD (NP (JJ intracellular) (NNS electrolytes)) (, ,) (NP (NN cell) (NN volume)) (, ,) (CC and) (NP (JJ Na-LRB-+-RRB--H+) (NN antiport))))) (VP (VBP have) (VP (VBN been) (VP (VBN found) (NP (-NONE- *-2)) (PP (IN in) (NP (NP (JJ human) (JJ mononuclear) (NNS leukocytes)) (PRN (-LRB- -LRB-) (NP (NN HML)) (-RRB- -RRB-))))))) (. .))
(S (NP-SBJ (NP (NN Binding)) (PP (IN of) (NP (JJ 125I-labeled) (NN aldosterone))) (PP (TO to) (NP (NP (NN plasma) (NNS membranes)) (PP (IN of) (NP (NN HML)))))) (VP (VBZ shares) (NP (JJ important) (NNS features)) (PP (IN with) (NP (DT these) (JJ functional) (NNS data)))) (. .))
(S (NP-SBJ (DT This)) (VP (VBZ includes) (NP-COOD (NP (NP (NP (DT a) (ADJP (RB very) (JJ low)) (JJ apparent) (NP (NP (NN dissociation) (NN constant)) (PRN (-LRB- -LRB-) (NP (NN Kd)) (-RRB- -RRB-)))) (PP (IN of) (NP (CD 0.1) (NN nM)))) (PP (IN for) (NP-COOD (CC both) (NP (NN aldosterone)) (CC and) (NP (NP (DT the) (NN effect)) (PP (IN on) (NP (DT the) (NN Na-LRB-+-RRB--H-LRB-+-RRB--antiport))))))) (, ,) (NP (DT a) (JJ high) (NN turnover) (NN rate)) (, ,) (CC and) (NP (NP (DT the) (ADJP (RB almost) (JJ exclusive)) (NN binding) (NN selectivity)) (PP (IN for) (NP (NN aldosterone)))))) (. .))
(S (NP-SBJ-COOD (NP (NN Dexamethasone)) (, ,) (NP (NN RU) (CD 26988)) (, ,) (NP (NN corticosterone)) (, ,) (NP (NN ouabain)) (, ,) (NP (NN amiloride)) (, ,) (CC and) (NP (NN 18-hydroxyprogesterone))) (VP (VBD were) (ADJP-PRD (JJ inactive)) (PP (IN as) (NP (NNS ligands)))) (. .))
(S (NP-SBJ (NN Deoxycorticosterone) (NN acetate)) (VP (VBD had) (NP (DT an) (JJ intermediate) (NN activity)) (PP (IN with) (NP (NP (DT an) (JJ apparent) (NN Kd)) (PP (IN of) (NP (CD 100) (NN nM)))))) (. .))
(S (NP-SBJ (DT These) (NNS findings)) (VP (VBP are) (NP-PRD (NP (DT the) (JJ first)) (SBAR (WHNP-101 (-NONE- 0)) (S (NP-SBJ (-NONE- *T*-101)) (VP (TO to) (VP (VB demonstrate) (S (NP-SBJ (NP (NN membrane) (NN binding)) (PP (IN of) (NP (NN aldosterone)))) (VP (VBG being) (ADJP-PRD (JJ compatible) (PP (IN with) (NP (NP (JJ major) (NNS aspects)) (PP (IN of) (NP (PRP$ its) (JJ nongenomic) (NNS effects)))))))))))))) (. .))
